FindTrial
Sign In

Clinical evaluation study: "Bupropion versus Psychodynamic mental training according to Dr. Grohs for smoke withdrawal" (Klinische Evaluierungsstudie: "Bupropion versus Psychodynamisches Mentaltraining nach Dr. Grohs zur Raucherentwöhnung" - Bupropion vs. PDM zur Raucherentwöhnung

Clinical evaluation study: "Bupropion versus Psychodynamic mental training according to Dr. Grohs for smoke withdrawal" (Klinische Evaluierungsstudie: "Bupropion versus Psychodynamisches Mentaltraining nach Dr. Grohs zur Raucherentwöhnung" - Bupropion vs. PDM zur Raucherentwöhnung

Status
Active, not recruiting
Phases
Phase 1Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-006189-32-AT
Enrollment
740
Registered
2006-02-01
Start date
2006-09-29
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nicotine addiction

Interventions

Trade Name: Zyban 150mg tablet Pharmaceutical Form: Coated tablet

Sponsors

Steiermärkische Gebietskrankenkasse
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: nicotine addiction Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: mental illness, psychiatric diagnosis (except nicotine or caffeine addiction) for Zyban: idiosyncrasy, epilepsy, bulimia, anorexia, zirrhosis, simultanous intake of MAO-inhibitors, brain tumour, alcohol or sedatives detoxication, pregnancy, nursing.

Design outcomes

Primary

MeasureTime frame
Main Objective: smoking cessation by means of psychodynamic mental training comparatatively tested with the recently most successfull IMP on the market (Zyban);Secondary Objective: One year abstinence Nicotine abstinence longer lasting than in Zyban treated comparison group.;Primary end point(s): last CO-breathing test after one year follow up of at least 740 subjects (370 subjects Zyban-treatment, 370 subjects Psychodynamic mental training)—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026